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ABSTRACT 
Treatment of the hormone refractory prostate cancer cell line DU 145 with sublethal concentrations 
of chemotherapeutic drugs has been reported to sensitise these cells to Fas mediated apoptosis. 
However, the mechanism by which this occurs has not been determined. Our group has shown that 
inhibition of JNK activity completely abrogates the effects of chemotherapeutic drugs. Using 
anisomycin, a potent JNK agonist, we have demonstrated a role for JNK in Fas mediated apoptosis in 
DU 145 cells. Inhibition of Caspase 8 and Caspase 9 completely inhibits this process which suggests 
that DU 145 cells require mitochondrial amplification of the Fas apoptotic signal. Furthermore, we 
have shown that inhibition of Fas mediated apoptosis is an early event in DU 145 cells, occurring 
upstream of Caspase 8 cleavage. It is hoped that identifying the target of JNK will allow novel 
therapies to be developed for the treatment of hormone refractory prostate cancer. Such therapies 
are especially important because no single or combined treatment to date has significantly 
prolonged survival in patients with hormone refractory prostate cancer. 
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INTRODUCTION 
Prostate cancer is the second most prevalent malignancy in the EU after lung cancer with about 
200000 new cases diagnosed and over 35000 deaths each year. In England and Wales, 15000 new 
cases and 8000 deaths are registered each year (Parkin et al, 2001). Although the prognosis is good 
for individuals with localised tumours, 10–20% of patients are diagnosed with metastatic prostate 
cancer (Crawford et al, 1999). These patients are usually treated with hormone ablation therapy 
which results in immediate tumour regression and temporary relief for the patient. However, 
hormone refractory prostate cancer invariably develops within 2–3 years of hormone ablation 
(Petrylak, 1999). This slowly proliferating cancer is extremely difficult to treat and the prognosis for 
the patient is generally poor. Over the past 5 years, chemotherapy has been used to improve the 
quality of life in patients with metastatic, hormone-refractory prostate cancer. No treatment has yet 
been found that cures the disease or even significantly prolongs survival (Petrylak, 1999). 
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Apoptosis, or programmed cell death (PCD), is characterised by morphological features including 
chromatin condensation, nuclear fragmentation, cell shrinkage, membrane blebbing and apoptotic 
body formation (Kerr et al, 1972). Although a variety of different environmental insults and signalling 
pathways can stimulate apoptosis in cells, most of these signals converge at a family of cysteine 
proteases called the caspases. Like many proteases, they are synthesised in an inactive form and 
cleavage into active caspases is essential for the proliferation of the apoptotic signal. Caspases can 
be divided into two main subfamilies, initiator caspases and effector caspases (Wolf and Green, 
1999). The Fas receptor is a member of the Tumour Necrosis Factor receptor superfamily and is 
expressed at the plasma membrane in a variety of tissues. Ligation of Fas ligand or a cross-linking 
antibody to the Fas receptor induces apoptosis in susceptible cells. Fas receptor clustering results in 
the recruitment and auto-cleavage of the initiator caspase, Procaspase 8, at the plasma membrane. 
Active Caspase 8 proceeds to cleave downstream cellular targets including the effector Caspases 3 
and 7, and the Bcl-2 family member Bid (Peter and Krammer, 1998). Often an amplification step is 
required for Caspase 3 cleavage and morphological apoptosis. Caspase 8 cleaves Bid into tBid, a pro-
apoptotic Bcl-2 family member that induces cytochrome c release and apoptosome formation. This 
amplification loop through the mitochondrion drives the apoptotic programme in type II cells 
(Scaffidi et al, 1999b). 
DU 145 cells, a hormone refractory prostate adenocarcinoma, are highly resistant to Fas mediated 
apoptosis in vitro. In a study performed using cell lines derived from prostate tumours with different 
pathological stages including DU 145, it was observed that ALVA-31 and PPC-1 were sensitive to Fas 
mediated apoptosis. These were reported to be isolated from primary prostatic tumours. In contrast, 
the cell lines LNCaP, DU 145 and PC-3 were resistant. These cell lines were reported to be derived 
from distant metastases. The authors correlated prostate cancer disease progression with resistance 
to Fas. Furthermore they suggest that this phenomenon may explain, at least in part, the inability to 
treat hormone refractory prostate cancer (Hedlund et al, 1998). The two other cell lines used in this 
study, JCA-1 and TSU-Pr1 have since been reclassified as bladder cancer cell lines (van Bokhoven et 
al, 2001). 
In order to study the resistance of hormone refractory prostate cancer to chemotherapy, the effects 
of chemotherapeutic drugs on DU 145 cells was explored (Uslu et al, 1997; Costa-Pereira and Cotter, 
1999). Our group discovered that sublethal concentrations of camptothecin, a novel topoisomerase I 
inhibitor, sensitised DU 145 cells to Fas mediated apoptosis by 20-fold (Costa-Pereira and Cotter, 
1999). Activation of the stress kinase JNK was found to be essential in potentiating Fas mediated 
apoptosis (Costa-Pereira et al, 2000). In this study, we use anisomycin, a potent activator of JNK, to 
underscore the role played by JNK in Fas mediated apoptosis in DU 145 cells. 
MATERIALS AND METHODS 
Cell lines and reagents 
DU 145 and Jurkat T cells were obtained from American Type Culture Collection (ATCC, Rockville, 
MD, USA). Cell culture reagents were purchased from Gibco BRL (UK) with the exception of foetal 
calf serum (FCS) (Sigma, UK). Anisomycin was purchased from Sigma (UK) and was dissolved in 
DMSO at a concentration of 5mgml−1. A working stock at 10μgml−1 in RPMI was prepared from the 
original stock. A FACScan (Beckton Dickinson, BD Biosciences, Germany) and Cell Quest software 
Version 3.3 (Beckton Dickinson) were used for all flow cytometry assays. Annexin V-FITC was 
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purchased from Bender MedSystems (Germany) and propidium iodide (PI) from Sigma (UK). TUNEL 
reagents were obtained from Roche (UK) and JC-1 was purchased from Molecular Probes 
(Netherlands). The antibodies used in this study were mouse anti-Fas IgM clone CH11, mouse anti-
Fas IgG for flow cytometry (Bender MedSystems, Germany), phospho-JNK (Thr183/Tyr185) clone G9 
and rabbit anti-Caspase 3 (Cell Signalling Technology, New England Biolabs UK), rabbit anti-JNK1 and 
rabbit anti-Fas ligand (Santa Cruz, USA), rabbit anti-Bid (BioSource International, USA), rabbit anti-
human caspase 8 (R&D Systems, UK) and mouse anti-β Actin clone AC-15 (Sigma, UK). All FITC and R-
Phycoerythrin conjugated secondary antibodies were purchased from Sigma (UK) and HRP 
conjugated secondary antibodies from DAKO (Denmark). The Caspase inhibitors z-IETD-fmk and z-
LEHD-fmk were obtained from Calbiochem (CN Biosciences UK). Enhanced Chemiluminescence 
Reagent (ECL) was purchased from Amersham Biosciences (UK). 
Cell culture and treatment 
DU 145 cells were cultured in RPMI 1640 medium supplemented with 5% FCS, 2mM L-Glutamine in 
the presence of 10IUml−1 penicillin-streptomycin. Jurkat cells were cultured in RPMI 1640 medium 
containing 10% FCS, 2mM L-Glutamine and 10IUml−1 penicillin-streptomycin. Cells were cultured at 
37°C in a humidified atmosphere with 5% CO2 and were routinely subcultured every 2–3 days. Prior 
to every experiment DU 145 cells were grown to 75% confluency and Jurkats were resuspended at 
0.5 million ml−1. DU 145 cells were pretreated with 250ngml−1 anisomycin for 10min before 
addition of 200ngml−1 anti-Fas IgM. 
Annexin V binding and propidium iodide uptake assay 
DU 145 and Jurkat cells were incubated with 250ngml−1 anisomycin and 200ngml−1 anti-Fas IgM for 
8h. The cells were subsequently harvested, washed once in PBS and resuspended in Annexin V 
binding buffer (150mM NaCl, 18mM CaCl2, 10mM HEPES, 5mM KCl, 1mM MgCl2). FITC conjugated 
Annexin V (1μgml−1), which binds specifically to apoptotic cells, was added to each sample and 
incubated at ambient temperature for 5min. Propidium iodide (50μgml−1), excluded from viable 
cells, was added immediately prior to reading the samples on the FACScan. Where indicated the 
Caspase 8 and Caspase 9 inhibitors were incubated for 10min at 50μM prior to treating the cells with 
anisomycin or Fas. 
DNA fragmentation assay 
TUNEL measures DNA fragmentation using the enzyme Terminal deoxynucleotide Transferase (TdT) 
to transfer multiple biotin labelled nucleotides to the 3′ hydroxyl groups of DNA. FITC conjugated 
Avidin can be used to stain this modified label. Using flow cytometry, cells with fragmented DNA in 
their nuclei display an increased fluorescent signal in the FL-1 channel relative to untreated cells. 
DU 145 and Jurkat cells were harvested, washed twice in PBS and fixed slowly in 1% 
paraformaldehyde (PFA) on ice for 15min. The cells were washed twice in PBS and resuspended in 
25μl reaction mixture (TdT buffer, 2.5mM CoCl2, Bio-16-dUTP and TdT enzyme). The DNA labelling 
reaction was allowed to proceed for 30min at 37°C. The cells were washed twice in PBS and 
resuspended in 50μl staining buffer (5×SSC, 5% wv−1 dry milk, 1×Avidin-FITC and 1/1000×Triton X-
100). The cells were stained for 30min at room temperature in the dark and washed twice in PBS. 
Flow cytometry and Cell Quest were used to collect and analyse the data. 
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Fas receptor expression 
0.5×106 cells were harvested per sample and washed twice in PBS. They were stained for 1h at 4°C 
with 20μgml−1 of the primary antibody mouse anti-Fas IgG. After another two washes with PBS, the 
cells were stained with the FITC conjugated secondary antibody sheep anti-mouse IgG for 1h at 4°C 
in the dark. Cells stained with secondary antibody alone were used to compensate for intrinsic 
fluorescence and non-specific binding of the secondary antibody. The cells were washed twice in PBS 
and the presence of Fas R was detected in FL-1 using a FACScan flow cytometer. 
Fas ligand expression 
0.5×106 cells were harvested per sample and were fixed slowly in ice cold 1% PFA for 15min. The 
cells were permeabilised overnight in 70% ethanol (−20°C) and stained with 2μgml−1 rabbit anti-Fas 
ligand or 2μgml−1 rabbit irrelevant IgG in IFATX (4% FCS, 150mM NaCl, 10mM HEPES, 0.1% sodium 
azide, 0.1% Triton X-100) for 1h at 4°C. Subsequently, the cells were stained for 1h with 12μgml−1 
FITC-conjugated anti-rabbit IgG in the dark at 4°C. Fas ligand expression was analysed on the 
FACScan using Cell Quest software. 
Mitochondrial membrane depolarisation 
The lipophilic cation called JC-1 is cell permeable and selectively accumulates in the mitochondria of 
live cells. When depolarisation of the mitochondria occurs, the emission spectrum of JC-1 changes 
from 590nm (its aggregated form) to 530nm (its monomeric form) and this can be analysed using 
flow cytometry. Depolarisation of mitochondria results in an increase in fluorescence in the FL-1 
channel, and a concurrent decrease in the FL-2 channel in flow cytometers. 
DU 145 cells were harvested, resuspended in RPMI+10% FCS and 2.5μgml−1 JC-1 was added. The 
samples were incubated at room temperature for 20min in the dark, washed twice in PBS and read 
on the FACScan. Analysis was carried out using Cell Quest software. 
SDS–PAGE and Western blot 
Protein extracts were prepared from cells using RIPA lysis buffer (50mM Tris, pH7.4; 150mM NaCl; 
1mM each of NaF, NaVO4 and EGTA; 1% NP40; 0.25% sodium deoxycholate; 0.2mM 
phenylmethylsulphonyl fluoride; 1μgml−1 each of antipain, aprotinin and chymostatin; 0.1μgml−1 
leupeptin; 4.0μgml−1 pepstatin) and 30μg of protein was loaded in each lane of an SDS 
polyacrylamide gel. Electrophoresis and Western blotting was subsequently carried out. Non-specific 
protein binding sites on the membrane were blocked using 5% dry milk in TBS+0.1% Tween-20 for 1h 
at room temperature. The membrane was stained with primary and peroxidase conjugated 
secondary antibodies according to the manufacturer's recommended protocol and labelled protein 
was detected using ECL. 
 
RESULTS 
Anisomycin activates JNK and sensitises DU 145 cells to Fas mediated apoptosis 
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The hormone refractory cell line DU 145 is highly resistant to Fas mediated apoptosis. This appears 
to be a common event during prostate cancer progression. Cell lines isolated from early stages of 
prostate cancer are usually sensitive to the Fas activating antibody anti-Fas IgM. Those cell lines 
derived from secondary tumours after hormone ablation therapy are generally resistant to Fas 
(Hedlund et al, 1998). Our group has previously shown that camptothecin, a Topoisomerase I 
inhibitor, sensitises DU 145 cells to Fas mediated apoptosis (Costa-Pereira and Cotter, 1999). 
Additional analysis identified activation of the stress kinase JNK as an integral event in this process 
(Costa-Pereira et al, 2000). In order to understand the mechanisms behind this sensitisation process 
we have used anisomycin, an agonist of the JNK pathway in mammalian cells, which is often used in 
studies involving JNK because of its specificity and potency in activating the JNK pathway. As 
expected, we found that anisomycin can act in synergy with Fas to induce apoptosis in DU 145 cells. 
Phosphatidylserine flipping, an early event during apoptosis was detected with FITC-conjugated 
Annexin-V using flow cytometry. Propidium iodide was used as a counter stain to distinguish 
between early and late apoptosis (Figure 1A). Flow cytometry was also used to detect DNA 
fragmentation, another hallmark of apoptosis, in TUNEL labelled DU 145 cells following incubation 
with anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1) (Figure 1B). This rapid onset of DNA 
fragmentation in our system is indicative of a stronger apoptotic stimulus when anisomycin is used 
to sensitise DU 145 cells to anti-Fas IgM in comparison with other cytotoxic drugs. Extensive DNA 
fragmentation was only observed after 48h when CPDD and CHX were used (Rokhlin et al, 1997; Uslu 
et al, 1997). Numerous reports have been described in the literature of both Caspase 8 dependent 
and Caspase 8 independent JNK activation during Fas mediated apoptosis. We used an antibody 
specific to phosphorylated JNK to assess the status of JNK activation in DU 145 cells after 1 and 8h 
incubation with anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1). We verified that JNK is not 
activated either transiently (1h) or prolonged (8h) with anti-Fas IgM (Figure 1c). As expected, 
anisomycin was found to stimulate prolonged JNK activation in DU 145 cells. An in vitro kinase assay 
using radiolabelled 32P was used to verify the activity of JNK (data not shown). 
Fas receptor and Fas ligand are not up-regulated by anisomycin in DU 145 cells 
Various reports have shown that down-regulation of Fas receptor or Fas ligand expression occurs in 
some cancer cells. In addition, expression of Fas ligand has been reported to increase following JNK 
activation in Jurkat cells (Herr et al, 2000). This increase in Fas ligand expression caused an increase 
in the kinetics of Fas mediated apoptosis. We assessed the expression of both Fas receptor and Fas 
ligand over an 8h period (1,2,4 and 8h) following incubation with anisomycin (250ngml−1) or anti-
Fas IgM (250ngml−1). Cell surface Fas receptor was expressed on 95% of DU 145 cells and its 
expression was not found to change following treatment with anisomycin or anti-Fas IgM (Figure 
2A). Similarly, Fas ligand was expressed in 90% of DU 145 cells and expression was not increased in 
DU 145 cells following incubation with anisomycin or anti-Fas IgM (Figure 2B). Western blot analysis 
confirmed that the expression of Fas receptor and Fas ligand was not upregulated following drug 
treatment (data not shown). 
Activation of Caspase 3 during Fas mediated apoptosis 
In order to delineate the mechanisms by which DU 145 cells are sensitised to Fas mediated 
apoptosis we analysed the major events during Fas mediated apoptosis. Most apoptotic stimuli 
converge on Caspase 3, a cysteine protease and the main effecter caspase during Fas mediated 
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apoptosis. Once activated, Caspase 3 cleaves a variety of substrates responsible for the 
morphological and biochemical changes observed during apoptosis (Nicholson, 1999). We found that 
both anisomycin and anti-Fas IgM treatment alone were insufficient for Caspase 3 activation in DU 
145 cells. However, co-incubation of cells with both anisomycin and anti-Fas IgM clearly potentiates 
the activation of Caspase 3 in DU 145 cells (Figure 3A). Anti-Fas IgM treated Jurkats are used as a 
positive control for Caspase 3 activation. Flow cytometric analysis confirmed that 70% of DU 145 
cells expressed the active form of Caspase 3 following treatment with both anisomycin and anti-Fas 
IgM (data not shown). 
Mitochondrial membrane depolarisation 
It has been shown that Fas receptor activation is often not sufficient for direct activation of Caspase 
3. These cells, known as type II cells, require an amplification signal through the mitochondrion. 
Caspase 8 cleaves and activates Bid, a pro-apoptotic Bcl-2 family member. This results in 
mitochondrial membrane depolarisation, cytochrome c release and amplification of the Fas 
apoptotic signal through Caspase 9 (Kim et al, 2000). Here we used the voltage sensitive, lipophilic 
fluorescent probe JC-1 to analyse the extent of mitochondrial membrane depolarisation in DU 145 
cells. Depolarisation of the mitochondrion causes an increase in FL-1 fluorescence and a concomitant 
decrease in FL-2 fluorescence when analysed by flow cytometry (Cossarizza et al, 1993). We found 
that stimulation of DU 145 cells for 8h with anisomycin (250ngml−1) or anti-Fas IgM (200ngml−1) 
alone did not result in permeability transition of the mitochondria (Figure 3B). This suggested that 
Fas mediated apoptosis is inhibited up-stream of mitochondrial depolarisation in DU 145 cells. 
Incubation of DU 145 cells with both anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1) resulted 
in mitochondrial depolarisation. We found that incubation of DU 145 cells with 50μM z-LEHD-fmk (a 
Caspase 9 specific inhibitor) completely abrogated apoptosis when incubated with anisomycin 
(250ngml−1) and anti-Fas IgM (200ngml−1) (Figure 3C). This suggested that mitochondrial 
membrane depolarisation and cytochrome c release are essential events for Fas mediated apoptosis 
in DU 145 cells. 
Caspase 8 activation in DU 145 cells 
The proximal caspase in the Fas apoptotic pathway is Caspase 8. Recruitment and auto-cleavage of 
Procaspase 8 occurs following Fas receptor activation in sensitive cells. Active Caspase 8 is 
tetrameric, consisting of two P14 and two P10 subunits. Using Western blot analysis, we found that 
Caspase 8 is not cleaved in DU 145 cells following treatment with anti-Fas IgM (200ngml−1) (Figure 
4A). Therefore, we concluded that inhibition of Fas mediated apoptosis occurred upstream of 
Caspase 8 activation in DU 145 cells. Caspase 8 cleavage products were only evident following 
incubation with both anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1). This was also true for 
the Caspase 8 substrate Bid (Figure 4B). Z-IETD-fmk (50μM), an irreversible inhibitor specific to 
Caspase 8, was found to completely protect against apoptosis induced by anisomycin (250ngml−1) 
and anti-Fas IgM (200ngml−1) (Figure 4C). Interestingly, this inhibitor also abolishes apoptosis 
associated with anisomycin alone. This suggests that low levels of Caspase 8 activation occur in DU 
145 cells following incubation with anisomycin alone. A dose titration of z-IETD-fmk confirmed that 
this inhibitor specifically inhibits Caspase 8 at 50μM (data not shown). FLIP is a family of proteins 
structurally related to Caspase 8 that inhibit Fas mediated apoptosis when overexpressed in cells 
(Scaffidi et al, 1999a). Two main isoforms of FLIP are expressed in cells, a long splice variant (FLIPL) 
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and a short splice variant (FLIPS). Using Western blot analysis we found that DU 145 cells express 
FLIPS. However, expression of this caspase 8 inhibitor does not appear to decrease following 
incubation with anisomycin (data not shown). 
 
DISCUSSION 
The sensitivity of prostate cancer cell lines to Fas mediated apoptosis has been shown to correlate 
with tumour stage, grade and resistance to chemotherapeutic drugs (Hedlund et al, 1998). Our 
group and others have shown that DU 145 cells are highly resistant to Fas mediated apoptosis. Co-
treatment with sublethal concentrations of chemotherapeutic drugs including cyclohexamide (CHX), 
cisplatin (CPDD), etoposide (VP16) and camptothecin was found to sensitise these cells to Fas 
mediated apoptosis (Uslu et al, 1997; Rokhlin et al, 1998; Costa-Pereira and Cotter, 1999) 
independently of new protein synthesis (Frost et al, 1999). Our group subsequently identified a key 
role for JNK in this process. DU 145 cells were co-treated with camptothecin and anti-Fas IgM and 
were completely protected from apoptosis by anti-sense oligonucleotides specific for JNK (Costa-
Pereira et al, 2000). In addition, camptothecin is a potent activator of JNK and sensitises DU 145 cells 
to Fas mediated apoptosis to a much greater extent than CHX, CPDD and VP16 (Costa-Pereira and 
Cotter, 1999). We have shown that anisomycin, a potent activator of JNK in mammalian cells, 
sensitises DU 145 cells to Fas mediated apoptosis to a similar extent as camptothecin. We felt that 
because camptothecin is also a topoisomerase I inhibitor and the mechanisms by which it activates 
JNK are unclear, anisomycin would present a better option for delineating the effects of JNK during 
Fas induced apoptosis. 
Binding of Fas ligand, or Fas activating antibodies, to Fas receptor results in DISC formation and 
prolonged JNK activation by either Caspase 8 dependent or Caspase 8 independent mechanisms 
(Chang et al, 1998; Rudel et al, 1998; Charette et al, 2001; Graves et al, 2001). We have shown that 
stimulating Fas R with anti-Fas IgM alone does not result in JNK activation in DU 145 cells. We found 
that mitochondrial membrane depolarisation only occurs in DU 145 cells co-stimulated with 
anisomycin and anti-Fas IgM. In addition Caspase 8 and Bid were only cleaved following incubation 
with both anisomycin and anti-Fas IgM. This suggests that anisomycin sensitises DU 145 cells to Fas 
mediated apoptosis at a point upstream of Caspase 8 cleavage, probably during DISC formation. 
There are some reports of caspase independent cell death following Fas R activation. These are 
mediated through kinases such as RIP and ASK1 (Holler et al, 2000; Charette et al, 2001). However, 
we have shown that both Caspase 8 and Caspase 9 inhibitors completely abrogate apoptosis induced 
by anisomycin and anti-Fas IgM in DU 145 cells. Therefore, anisomycin sensitised DU 145 cells to 
apoptosis mediated by Fas that is dependent on both Caspase 8 activity to initiate the pathway and 
Caspase 9 activity as an amplification step required for Caspase 3 activation and apoptosis. 
The principal apoptotic pathway activated by many anti-cancer drugs is the Fas apoptotic pathway. 
DU 145 cells incubated with toxic concentrations of 9-amino camptothecin were found to increase 
Fas receptor and Fas ligand expression and decrease c-FLIPS. Apoptosis could be inhibited by 
transient overexpression of c-FLIPS, suggesting that 9-amino camptothecin induces apoptosis 
through the Fas apoptotic pathway (Chatterjee et al, 2001). However, we found no evidence for 
increased Fas receptor or Fas ligand expression following incubation with anisomycin. We did 
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observe a decrease in Fas ligand expression after apoptotic body formation in cells incubated with 
both anisomycin and anti-Fas IgM. This is most probably due to the shedding of membrane bound 
Fas ligand and is irrelevant to the initiation of apoptosis in these cells. We also analysed FLIPS 
expression but no changes were observed following treatment with anisomycin. Chemotherapeutic 
drugs have also been reported to activate the Fas apoptotic pathway without upregulation of Fas 
ligand or Fas receptor. Apoptosis induced by CPDD, VP16 and vinblastine (VB) was shown involve Fas 
receptor clustering and Caspase 8 activation and was independent of Fas ligand in various colon 
cancer cells and leukaemia cells (Micheau et al, 1999). It is possible that anisomycin is inducing Fas 
receptor aggregation independently of anti-Fas IgM but this is highly unlikely in light of our results. It 
seems more probable that JNK activation enhances Fas receptor aggregation and DISC formation 
through its interaction with some key regulator of DISC formation in DU 145 cells. 
Conventional chemotherapy has been unsuccessful in treating prostate cancer. No single or 
combined chemotherapy regime has been identified that significantly enhances long term survival. 
This may be due, at least in part, to the resistance developed to Fas mediated apoptosis in hormone 
refractory prostate cancer. We have sensitised DU 145 cells to Fas mediated apoptosis using the JNK 
agonist anisomycin. In addition we have traced the effects of JNK to a point upstream of Caspase 8 
cleavage. It is hoped that by understanding this process novel drug targets may be identified that 
improve the treatment of hormone refractory prostate cancer. 
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FIGURE LEGENDS 
Figure 1 
Anisomycin sensitised the androgen independent cell line DU 145 to Fas mediated apoptosis. DU 145 
cells were pre-treated with anisomycin (250 ng ml−1) for 10 min before the addition of anti-Fas IgM 
(200 ng ml−1). Cells were stained with Annexin V and PI (A) or TUNEL (B) after 8 h incubation as 
described in the Materials and Methods section. Flow cytometry was used to visualise the extent of 
apoptosis. Data are representative of at least three independent experiments. (C) Anisomycin, not 
anti-Fas IgM, stimulates prolonged JNK activation in DU 145 cells. Western blot analysis was used to 
detect active JNK in untreated DU 145 cells, or cells treated with anisomycin (250 ng ml−1), anti-Fas 
IgM (200 ng ml−1) or both anisomycin and anti-Fas IgM for 1 and 8 h. Total JNK expression was 
determined to ensure equal protein loading. 
Figure 2 
Flow cytometric analysis of Fas receptor (A) or Fas ligand (B) expression in untreated DU 145 cells or 
following 8 h incubation with anisomycin (250 ng ml−1), anti-Fas IgM (200 ng ml−1) or both. Data are 
representative of at least three independent experiments and similar data were obtained for 
incubations of 1, 2 and 4 h. 
Figure 3 
(A) Untreated DU 145 (1) cells or cells treated for 8 h with anisomycin (250 ng ml−1) (2), anti-Fas IgM 
(200 ng ml−1) (3) or both (4) were stained for Caspase 3 cleavage. Jurkats treated with anti-Fas IgM 
(200 ng ml−1) for 4 h were used as a positive control (5). (B) Mitochondrial membrane depolarisation 
(ΔΨ) was detected in DU 145 cells using the lipophilic JC-1 probe, as described previously. ΔΨ was 
only observed in DU 145 cells treated for 8 h with both anisomycin (250 ng ml−1) and anti-Fas IgM (200
ng ml−1). (C) DU 145 cells were pre-treated with 50 μM z-LEHD-fmk (white columns) or a DMSO 
control (black columns) for 10 min before treating with anisomycin (250 ng ml−1) and anti-Fas IgM (200
ng ml−1) for 8 h. Apoptosis was assessed by staining the cells with Annexin V-FITC and PI. The error 
bars represent standard deviation after three independent experiments. 
Figure 4 
Inhibition of Fas mediated apoptosis occurs upstream of Caspase 8 cleavage in DU 145 cells. (A) 
Western blot analysis of Caspase 8 in untreated DU 145 cells (1) or following incubation with 
anisomycin (250 ng ml−1) (2), anti-Fas IgM (200 ng ml−1) (3) or both (4) for 8 h. Untreated (5) and anti-
Fas IgM treated (200 ng ml−1 anti-Fas IgM, 4 h) (6) Jurkat cells were used as a positive control for the 
P14 and P10 Caspase 8 cleavage products. β-Actin was also probed to ensure equal protein loading. 
(B) Bid expression and cleavage was analysed by Western blot in untreated DU 145 cells (1) or in 
cells incubated with anisomycin (250 ng ml−1) (2), anti-Fas IgM (200 ng ml−1) (3) or both (4) for 8 h. 
Jurkats untreated (5) or treated with anti-Fas IgM (200 ng ml−1) for 4 h (6) are used as a positive 
control. (C) DU 145 cells were pre-treated with 50 μM z-IETD-fmk (white columns) or a DMSO control 
(black columns) for 10 min before treating with anisomycin and anti-Fas IgM as before. Apoptosis was 
determined by staining with both Annexin V and PI after 8 h. Data is representative of three 
independent experiments. 
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